TY - JOUR T1 - Prolaktinomanın Klinik ve Laboratuar Özellikleri :Tek Merkez Deneyimi TT - Clinical and Laboratory Features of Prolactinoma: Single Center Experience AU - Kesebi Isganderov, Duygu AU - Kebapçı, Nur PY - 2024 DA - August Y2 - 2024 DO - 10.58961/hmj.1494250 JF - Hipokrat Tıp Dergisi JO - HTD / HMJ PB - Bandırma Onyedi Eylül Üniversitesi WT - DergiPark SN - 2791-9935 SP - 34 EP - 39 VL - 4 IS - 2 LA - tr AB - Amaç: Çalışmamızın amacı prolaktinomaların sıklığı, tanı ve tedavisi ile klinik seyrini ortaya koyarak epidemiyolojik çalışmaların hastalıkların klinik yönetimi açısından önemine vurgu yapmaktır.Gereç ve yöntem: 356 prolaktinoma hastası çalışmaya dahil edildi. Hastaların hastane bilgi yönetim sistemi ve hastaların kayıtlı olduğu endokrin dosyalarından bilgileri tarandı. Taranan bilgiler; hasta yaşı, cinsiyet, tanı yaşı, takip yılı, başvuru şikayeti, adenomun boyutu, yerleşimi, hipofiz adenomunun tanı anında ve tedavi sonrası hormon düzeyleri, varsa kullanılan medikal tedavi çeşidi, hipofiz adenomunun operasyon sayısı ve şekli, medikal yada cerrahi tedavi öncesi ile sonrası adenom boyutu ve varsa rezidü/nüks hipofiz adenom boyutu, kiazma basısı, postop hormon aktivitesi, adenoma yönelik varsa RT öyküsüydü.Bulgular: 356 prolaktinoma olgularının cinsiyet dağılımına bakıldığında 305’inin (%85.7) kadın, 51’inin (%14.3) erkek olduğu görüldü (p4cm) olarak kaydedildi. Mikroadenomlar ise kadınlarda daha sık (%80) görüldü(p KW - Prolaktinoma KW - infertilite KW - mikroadenomi KW - amenore/oligoamenore N2 - Aim: The aim of our study is to emphasize the importance of epidemiological studies in terms of clinical management of diseases by revealing the frequency, diagnosis, treatment and clinical course of prolactinomas.Materials and Methods: 356 prolactinoma patients were included in the study. The patients' information have taken from the hospital information management system and the endocrine files. Scanned information; patient age, gender, age at diagnosis, follow-up year, complaint at presentation, size and location of the adenoma, hormone levels of the pituitary adenoma at the time of diagnosis and after treatment, type of medical treatment used, if any, number and type of operations of the pituitary adenoma, adenoma before and after medical or surgical treatment, size and residual/recurrent pituitary adenoma size, if any, chiasm compression, postoperative hormone activity, and history of RT for adenoma, if any.Results: 356 prolactinoma cases was examined, it was seen that 305 (85.7%) were female and 51 (14.3%) were male (p4cm). Microadenomas were seen more frequently in women (80%) (p CR - Kovacs K. Tumors of the pituitary gland. Atlas of Tumor Pathology fascicle 21, 2nd series. 1986:1-269. CR - Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004;101(3):613-9. CR - Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. American Journal of Neuroradiology. 1994;15(4):675-9. CR - Erbaş T. Hipofiz Adenomlarının Endokrinolojik Değerlendirilmesi. Hipofiz Adenomları. 2008;1:138-65. CR - Glezer A, Bronstein MD. Prolactinoma. Arquivos Brasileiros de Endocrinologia & Metabologia. 2014;58(2):118-23. CR - Grubu THÇ. Hipofiz Hastaliklari Tani, Tedavi ve izlem Kilavuzu. Ankara, Türkiye Endokrinoloji ve Metabolizma Dernegi. 2019. CR - Yatavelli RKR, Bhusal K. Prolactinoma. StatPearls [Internet]: StatPearls Publishing; 2018. CR - Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re‐definition? A study of 226 patients with histologically verified non‐functioning pituitary macroadenoma. Clinical endocrinology. 2006;65(4):524-9. CR - Porta‐Etessam J, Ramos‐Carrasco A, Berbel‐García Á, Martínez‐Salio A, Benito‐León J. Clusterlike headache as first manifestation of a prolactinoma. Headache: The Journal of Head and Face Pain. 2001;41(7):723-5. CR - Duskin-Bitan H, Shimon I. Prolactinomas in males: and differences? Pituitary. 2020;23(1):52-7. CR - Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4769-75. CR - Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. European Journal of Endocrinology. 2014;171(4):519-26. CR - Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine reviews. 2006;27(5):485-534. CR - Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European journal of endocrinology. 2003;148(3):325-31. CR - Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273-88. CR - Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinology and metabolism clinics of North America. 2008;37(1):67-99. CR - Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6. CR - Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical endocrinology. 2006;65(2):265-73. UR - https://doi.org/10.58961/hmj.1494250 L1 - https://dergipark.org.tr/tr/download/article-file/3974600 ER -